TRUP TRUPANION
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 9 analyst firms say about TRUPANION: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 9 analyst/firm records · 9 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Average target is not above the current price
- Russell 2000 · Safest consensus · 6MNot scored · Average target is not above the current price
Recent analyst activity · last 90 days
Our tracked history has 6 reports on TRUP from 6 analyst firms in the last 90 days (9 firms in the past year).
Comparing each firm's latest target with its previous one: 3 lowered it.
Ratings, latest available report against the previous one: 0 upgrades and 1 downgrade.
Latest observed target change: Cantor Fitzgerald lowered its target from $34.00 (set 9 Apr 2026) to $30.00 on 7 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Atlantic Securities | Unnamed analyst | — | 15 Jul 2026 | 42.00 USD |
| Bank of America Securities | Joshua Shanker | Buy | 14 Apr 2026 | 59.00 USD |
| Cantor Fitzgerald | Ryan Tunis | Hold | 7 Oct 2026 | 30.00 USD |
| Piper Sandler | David Westenberg | Hold | 26 Aug 2026 | 32.00 USD |
| Raymond James | Wilma Burdis | Hold | 17 Aug 2026 | — |
| Stifel | Jonathan Block | Hold | 20 Aug 2026 | 29.00 USD |
| Weiss Ratings | Unnamed analyst | — | 29 Sep 2026 | — |
| William Blair | Brandon Vazquez | Buy | 13 Feb 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 24 Aug 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:08 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.